Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
$15.87
$0.42(2.31%)
At close: 4:00 PM EST
$15.87
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$13.83 - $36.91
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.86M
Market Cap
$11.82B
Enterprise Value$11.59B
Total Cash (Recent Filing)$238.88M
Total Debt (Recent Filing)$5.43M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Feb 23, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding744,442,570
10 Day Avg. Volume2,317,985
30 Day Avg. Volume2,863,510
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)32.99
Price to Sales (P/S)0.00
P/FCF Ratio-90.17
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-770.29
Enterprise Value/Ebitda-12.58
Forecast
1Y Price Target
$57.98Price Target Upside265.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy AdvantageClinical data indicating ivonescimab outperforms an established PD-1 therapy in certain first-line lung cancer patients and in EGFR-mutant cases suggests a meaningful efficacy edge that could support wider adoption.
Regulatory ProgressFDA acceptance of the Biologics License Application initiates formal U.S. review and signals the submission met completeness standards, reducing near-term regulatory uncertainty.
Strategic CollaborationCollaboration with GlaxoSmithKline to test ivonescimab with a B7-H3 antibody-drug conjugate expands combination development opportunities and shares operational responsibilities, improving partner incentives to advance programs.
Bears Say
Approval Risk Tied To Survival DataU.S. approval remains uncertain because regulators commonly expect statistically significant overall survival benefits in this treatment setting, keeping approval risk elevated.
Clinical Delays And Financing PressurePotential delays or failures in ivonescimab studies combined with the risk of future capital raises could create operational setbacks and lead to shareholder dilution.
Trial Design And InterpretabilityThe global HARMONi trial structure, including heavy participation from China, increases complexity and could raise regulatory scrutiny around trial conduct and the interpretation of survival results.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $13.83 and its highest was $36.91 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $11.82B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Feb 23, 2026 which is in 3 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Oct 20, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.14.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 744,442,570 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -4.526%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.98 (265.34% Upside)
$57.98 (265.34% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 40.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.66%
12-Months-Change
Fundamentals
Return on Equity
-292.49%
Trailing 12-Months
Asset Growth
-47.95%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results and expansion plans with multiple Phase III trials, indicating significant progress and potential for ivonescimab in various cancer treatments. However, financial concerns and increased expenses were noted as challenges.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$57.98
▲(265.34% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---